Market Overview

UPDATE: Bank of America Raises PO to $130 on Alexion Pharmaceuticals on Soliris Data

Related ALXN
UPDATE: 8-K from Alexion Pharma Shows FDA Issued Form 483 at Aug. Inspection of Site, Does Not Expect Material Financial Effect Related to FDA Concern
Alexion Initiates Multinational Registration Trial of Eculizumab for Prevention of DGF after Kidney Transplantation

Bank of America reiterated its Buy rating on Alexion Pharmaceuticals (NASDAQ: ALXN) and raised its price objective from $118 to $130.

Bank of America commented, "We are increasing our PO from $118 to $130 to reflect a higher probability of success for Soliris in neuromyelitis optica (NMO) following impressive Phase 2 data presented yesterday. We removed MG and the nondescript "other indications" for Soliris from our valuation, as current data suggests NMO may be the final large indication beyond PNH and aHUS (STEC and AMR incremental drivers)."

Alexion Pharmaceuticals closed at $111.30 on Tuesday.

Latest Ratings for ALXN

DateFirmActionFromTo
Sep 2014SunTrust Robinson HumphreyInitiates Coverage onBuy
Jul 2014Credit SuisseMaintainsNeutral
Jul 2014JP MorganMaintainsOverweight

View More Analyst Ratings for ALXN
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (ALXN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters